APGE VS OLMA Stock Comparison

PerformanceEarningsVolatilitySentimentTechnicalsProfit
PerformanceEarningsVolatilitySentimentTechnicalsProfit

Performance

APGE
28/100

APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.

OLMA
100/100

OLMA returned 376.81% in the last 12 months. Based on SPY's performance of 11.93%, its performance is above average giving it a score of 100 of 100.

Earnings

APGE
100/100

APGE has missed earnings 1 times in the last 20 quarters.

OLMA
10/100

OLMA has missed earnings 6 times in the last 20 quarters.

Volatility

APGE
44/100

APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

OLMA
61/100

OLMA has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

Sentiment

APGE

"Sentiment" not found for APGE

OLMA
71/100

OLMA had a bullish sentiment score of 71.10% across Twitter and StockTwits over the last 12 months. It had an average of 3.67 posts, 1.46 comments, and 1.48 likes per day.

Technicals

APGE

"Technicals" not found for APGE

OLMA
75/100

OLMA receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

Profit

APGE

"Profit" not found for APGE

OLMA
10/100

Out of the last 16 quarters, OLMA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Apogee Therapeutics, Inc. Common Stock Summary

Nasdaq / APGE
Healthcare
Biotechnology
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Olema Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / OLMA
Healthcare
Biotechnology
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.